- Six-month data from PaTH Forward open-label extension support potential use of TransCon PTH as a hormone replacement therapy for adult hypoparathyroidism – - Conference call Tuesday, September 29 at ...
In top-line data from the Pathway phase III trial with Transcon PTH in hypoparathyroidism, Ascendis Pharma A/S provided “what many have been waiting for: a way of therapy to not only boost serum ...
– For the primary composite endpoint, TransCon PTH demonstrated a response rate of 78.7% compared to 4.8% for control (p-value 600 mg/day of calcium supplements) with no increase in prescribed study ...
Credit: Getty Images. The phase 3 PaTHway trial included 82 adults with chronic hypoparathyroidism. Positive topline results were announced from a phase 3 trial evaluating the efficacy and safety of ...
- Oral presentation of results showed sustained improvements through Week 52, as well as safety and tolerability similar to that previously reported for the initial 26-week blinded portion of the ...
COPENHAGEN, Denmark, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (ASND) today announced that a new pooled analysis showed sustained and clinically meaningful improvements in renal function ...
The information provided in response to the FDA’s Complete Response Letter "constituted a major amendment to the NDA" requiring more time for review. The Food and Drug Administration (FDA) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results